Objective—To determine the efficacy of triamcinolone
acetonide topical solution (TTS) in dogs for use in
reduction of clinical signs of pruritic inflammatory skin
diseases of a known or suspected allergic basis and
to evaluate adverse effects associated with TTS
Animals—103 pruritic adult dogs with known or suspected
allergic skin disease.
Procedure—Dogs were treated for 4 weeks with TTS
or with vehicle solution (control dogs) in a multiplecenter
study. Clinical signs were scored by owners
and by examining veterinarians before and after treatment.
Blood samples obtained before and after treatment
were subjected to routine hematologic and
serum biochemical analyses.
Results—Treatment success, as defined by an
improvement of at least 2 of 6 grades in overall
clinical score, was evident in 35 of 52 (67%) TTStreated
dogs (mean improvement, 1.98) and 12 of
51 (24%) control dogs (mean improvement, 0.29).
For several criteria, TTS was significantly more
effective than vehicle in reducing clinical signs.
Minor alterations in hematologic determinations in
TTS-treated dogs were limited to slightly lower
total leukocyte, lymphocyte, and eosinophil counts
after treatment. Minor adverse effects were reported
by owners in 6 of 52 (12%) TTS-treated and 9 of
51 (18%) control dogs.
Conclusions and Clinical Relevance—Triamcinolone
used as a spray solution at a concentration approximately
one-sixth the concentration of triamcinolone
topical preparations currently available for veterinary
use is effective for short-term alleviation of allergic
pruritus in dogs. Adverse effects are few and mild
and, thus, do not preclude prolonged treatment with
the solution. (Am J Vet Res 2002;63:408–413)